Between 2015 and 2021, NICE technology appraisals and clinical guidelines recommended that, for most people with T2DM, several second‐line oral treatment options should be available, including sodium‐glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or the lower‐cost option of sulphonylureas (SUs).19, 20. Here, SLC5A2 is linked to type 2 diabetes mellitus.